What will be Sarepta's stock price range in Q4 2024? | Categorical | | | 6 months ago | |
Will Sarepta's stock reach $200 by end of 2024? | Binary | | | 6 months ago | |
Will Sarepta report revenue growth by Q4 2024? | Binary | | | 6 months ago | |
What will Sarepta's Q4 2024 revenue be? | Categorical | | | 6 months ago | |
Will FDA grant full approval for non-ambulatory DMD patients by end of 2024? | Binary | | | 6 months ago | |
Sarepta Stock $200 by 2024? | Binary | | | 6 months ago | |
Sarepta Elevidys $1B Annual Sales by 2025? | Binary | | | 6 months ago | |
Sarepta Stock Price at End of Q4 2024 | Categorical | | | 6 months ago | |
Sarepta Elevidys Full FDA Approval for Non-Amb Patients by June 2025? | Binary | | | 6 months ago | |
Will Sarepta's stock price reach BofA's target of $213 by December 31, 2024? | Binary | | | 6 months ago | |
How many patients will be prescribed Elevidys by the end of 2024? | Categorical | | | 6 months ago | |
Which analyst's price target for Sarepta will be closest to actual stock price on December 31, 2024? | Categorical | | | 6 months ago | |
Will Sarepta's Elevidys annual revenue surpass $700 million by 2025? | Binary | | | 6 months ago | |
Sarepta stock price increases by 50% or more by end of 2024? | Binary | | | 6 months ago | |
Elevidys generates $500mn or more in revenue by end of 2024? | Binary | | | 6 months ago | |
Sarepta's market cap ranking among biotechnology companies by end of 2024? | Categorical | | | 6 months ago | |
Number of new gene therapy approvals by FDA by end of 2024? | Categorical | | | 6 months ago | |
Full FDA approval for Elevidys for non-ambulatory patients by end of 2024? | Binary | | | 6 months ago | |
What will be Sarepta's stock price range by end of 2024? | Categorical | | | 6 months ago | |
Will Sarepta's stock reach $213 by end of 2024? | Binary | | | 6 months ago | |
Will FDA revisit Elevidys approval in 2024? | Binary | | | 6 months ago | |
What will be the revenue from Elevidys gene therapy by end of 2024? | Categorical | | | 6 months ago | |
How many new DMD patients will receive Elevidys treatment by end of 2024? | Categorical | | | 6 months ago | |
Will Sarepta Therapeutics' stock price increase by at least 20% by September 30, 2024? | Binary | | | 6 months ago | |
What will be Sarepta Therapeutics' revenue from Elevidys by end of 2024? | Categorical | | | 6 months ago | |
ELEVIDYS best-selling gene therapy in US by end of 2024? | Categorical | | | 6 months ago | |
ELEVIDYS receives EU approval by end of 2024? | Categorical | | | 6 months ago | |
Sarepta stock price exceeds $200 by end of Q1 2025? | Categorical | | | 6 months ago | |
ELEVIDYS further label expansion by mid-2025? | Binary | | | 6 months ago | |
ELEVIDYS full approval for non-ambulatory patients by end of 2024? | Binary | | | 6 months ago | |
ELEVIDYS $500 million sales by end of 2024? | Binary | | | 6 months ago | |
Will Sarepta Therapeutics face legal action due to the censorship incident by December 31, 2024? | Binary | | | 5 months ago | |
Will Sarepta Therapeutics stock price drop by more than 10% following the censorship incident by August 31, 2024? | Binary | | | 5 months ago | |
How many additional regulatory approvals will Elevidy receive by end of 2024? | Categorical | | | 6 months ago | |
Total DMD Patients Treated with Elevidys by 2024 | Categorical | | | 6 months ago | |
Sarepta Total US Sales from Elevidys by 2025 | Categorical | | | 6 months ago | |
What will be Elevidys' peak annual revenue by the end of 2026? | Categorical | | | 6 months ago | |
Percentage increase in DMD patients treated with Elevidys by end of 2024? | Categorical | | | 6 months ago | |
Will Elevidys face additional regulatory scrutiny in 2024? | Binary | | | 6 months ago | |
Will FDA revoke Elevidys approval by end of 2024? | Binary | | | 6 months ago | |
Will Elevidys be covered by Medicare and Medicaid by end of 2024? | Binary | | | 6 months ago | |
Will Sarepta and Arrowhead initiate ARO-DUX4 clinical trial by June 30, 2025? | Binary | | | 27 days ago | |
How will the market react to Sarepta and Arrowhead's collaboration by March 31, 2025? | Categorical | | | 27 days ago | |
What major milestone will Sarepta and Arrowhead achieve by end of 2025? | Categorical | | | 27 days ago | |
Will Sarepta's equity in Arrowhead appreciate by more than 35% by end of 2025? | Binary | | | 27 days ago | |
Will Sarepta and Arrowhead announce a new siRNA program by end of 2025? | Binary | | | 27 days ago | |
Will Sarepta Therapeutics issue a public apology for the censorship incident by December 31, 2024? | Binary | | | 5 months ago | |
Will the FDA revise its approval for Elevidys by the end of 2024? | Binary | | | 6 months ago | |
Which siRNA therapy will reach Phase 2 trials first by end of 2025? | Categorical | | | 27 days ago | |
What changes will Sarepta Therapeutics make to its gene therapy approach by December 31, 2024? | Categorical | | | 5 months ago | |
What will be the outcome of Sarepta Therapeutics' relationship with the Duchenne patient advocacy organization by December 31, 2024? | Categorical | | | 5 months ago | |
What will be the public reaction to Sarepta Therapeutics' gene therapy following the censorship incident by December 31, 2024? | Categorical | | | 5 months ago | |
What will be the market response to Elevidys gene therapy by end of 2024? | Categorical | | | 6 months ago | |
How many countries will approve Elevidys by end of 2024? | Categorical | | | 6 months ago | |
